# A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

> **NCT07068165** · PHASE2,PHASE3 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 198 (estimated)

## Conditions studied

- IgG4 Related Disease

## Interventions

- **DRUG:** 5mg lenalidomide
- **DRUG:** 10mg lenalidomide
- **DRUG:** Prednisone monotherapy

## Key facts

- **NCT ID:** NCT07068165
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2028-07-20
- **Final completion:** 2028-08-20
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07068165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07068165, "A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07068165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*